Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data

Yoo, WH; Kang, YM; Kim, DW; Kang, EH; Lee, YA; Suh, CH; Sung, YK; Lee, SH; Gu, DH; Lee, J; Choe, JY

Choe, JY (通讯作者)，Daegu Catholic Univ, Div Rheumatol, Dept Internal Med, Sch Med, 33 Duryugongwon Ro 17 Gil, Daegu, South Korea.

RHEUMATOLOGY AND THERAPY, 2023; 10 (2): 329

Abstract

IntroductionSB4 is the first approved biosimilar of etanercept, a biologic tumor necrosis factor inhibitor, to treat various autoimmune diseases inclu......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索